Massimo Calafiore Named Orthofix President and CEO

Orthofix Medical Inc. has a new leader.

The company has named Massimo Calafiore as president and CEO. Currently the CEO of LimaCorporate S.p.A., Calafiore is expected to assume his new position in early 2024, following the completion of LimaCorporate’s previously announced acquisition by Enovis Corporation for €800 million. At that time, Calafiore is also expected to join Orthofix’s Board of Directors. 
 
“The Board of Directors unanimously determined that Massimo is the right choice to lead Orthofix given his exceptional track record of delivering value creation and his extensive knowledge of the medical device industry, specifically within orthopedics and spine,” Orthofix Board Chair/Interim CEO Catherine Burzik said. “Throughout his career, Massimo has demonstrated his ability to unlock value opportunities for multi-segmented, global businesses. He has successfully driven sales and commercial operations to achieve both industry leading profitability and growth. Importantly, he has proven experience integrating companies and building high performing teams.” 
 
Calafiore is an accomplished global business leader with an excellent track record across multiple companies in the orthopedics and spine industry. Throughout his career he has demonstrated a commitment to operating excellence, ethical integrity and DE&I values. He has been CEO of LimaCorporate since September 2022 and during his tenure, Calafiore strengthened and reshaped the company’s strategy and culture priorities, with an emphasis on fostering, mentoring and retaining talent. His leadership resulted in consecutive quarter-over-quarter above-market growth; best-in-class EBITDA margins; and substantial improvement in employee engagement and retention.
 
Prior to LimaCorporate, Calafiore served as executive vice president and chief commercial officer of NuVasive Inc. and delivered consecutive quarter-over-quarter above-market growth in all core geographies, including the United States, APAC (Asia-Pacific), EMEA (Europe, Middle East, Africa), and Japan, and successfully launched multiple products globally, which became foundational to NuVasive’s portfolio offering. At the beginning of his NuVasive tenure, Calafiore served as president of NuVasive Specialized Orthopedics (formerly Ellipse Technologies). In this role, he helped to further integrate the Ellipse business with NuVasive, achieving multiple quarters of accelerated revenue growth with above-market operation margin expansion. NuVasive Specialized Orthopedics currently is an important player in complex trauma and limb reconstruction for adults and children, a market segment where Orthofix is also a recognized leader.
 
Earlier in his career, Calafiore worked for Waldemar Link GmbH & Co. KG and served in various leadership roles across multiple business segments, including orthopedics, lower extremities, and spine. He supervised the sales of the STAR Ankle to Small Bone Innovations and the PCM Cervical disc to NuVasive. 
 
Calafiore earned an M.Sc. in mechanical engineering from the University of Catania and an MBA from New York University.

“Having worked in orthopedics and spine throughout my entire career, I know Orthofix well and have long admired the company and its team,” Calafiore stated. “I was attracted to Orthofix given the many growth opportunities created by its unique, broad-based portfolio and high-quality distributor relationships. I am also impressed with the innovative solutions Orthofix has developed to meet the needs of surgeons and the patients it serves. At this pivotal time for the company, I look forward to working with the board and leadership team to capture Orthofix’s significant profitable growth potential and drive enhanced shareholder value.” 
 
The company also announced that Burzik will not stand for reelection to the board at its 2024 Annual Meeting. “It is an honor to serve as Interim CEO and work closely with Orthofix’s amazing employees,” Burzik said. “The organization is on solid footing, and I will be delighted to turn the company over to Massimo’s very capable hands and plan to work closely with him in the following months to ensure a seamless transition.”  
 
Orthofix’s board retained Heidrick & Struggles in its search for a new CEO.
 
Orthofix is a global spine and orthopedics company with a portfolio of biologics, spinal hardware, bone growth therapies, specialized orthopedic solutions, and a surgical navigation system. Its products are distributed in approximately 68 countries worldwide.  
The company is headquartered in Lewisville, Texas, and has primary offices in Carlsbad, Calif., with a focus on spine and biologics product innovation and surgeon education, and Verona, Italy, with an emphasis on product innovation, production, and medical education for orthopedics. The combined company’s global R&D, commercial and manufacturing footprint also includes facilities and offices in Irvine, Calif.; Toronto, Canada; Sunnyvale, Calif.; Wayne, Pa.; Olive Branch, Miss.; Maidenhead, U.K.; Munich, Germany; Paris; and Sao Paulo, Brazil.